SLAMF7 CAR-T cells

SLAMF7 CAR-T cells are genetically engineered T cells expressing a chimeric antigen receptor (CAR) that targets SLAMF7 (Signaling Lymphocytic Activation Molecule Family member 7, also known as CS1), an antigen highly and uniformly expressed on malignant plasma cells in multiple myeloma. Upon engagement, these CAR-T cells recognize and lyse SLAMF7-expressing myeloma cells, demonstrating potent anti-myeloma activity in both preclinical and early clinical studies. Both autologous and allogeneic versions of SLAMF7 CAR-T cells (e.g., CARAMBA and UCARTCS1) have been developed: the former generated from the patient's own cells, the latter as an off-the-shelf product from healthy donors. Notably, the CARAMBA project utilizes virus-free Sleeping Beauty (SB) transposon technology for gene transfer, aiming to improve manufacturing efficiency and safety[2][5][7]. A unique consideration for SLAMF7 CAR-T is their potential for fratricide, as SLAMF7 is expressed on some normal lymphocytes, which the therapy can selectively deplete, although SLAMF7-negative/low lymphocyte populations are generally preserved[1][3][5][6]. Clinical trials are underway primarily in patients with relapsed/refractory multiple myeloma.

Other names

SLAMF7 CAR-T cellsSLAMF-7 CAR-T cellsSLAMF 7 CAR-T cellsSLAMF7-CAR T cellsSLAMF-7-CAR T cellsSLAMF 7-CAR T cellsanti-SLAMF7 CAR-Tanti-SLAMF-7 CAR-Tanti-SLAMF 7 CAR-TCARAMBA cellsUCARTCS1UCARTCS-1UCARTCS 1CS1 CAR-TCS-1 CAR-TCS 1 CAR-T